CGM device returns 93 per cent accuracy in type 1 and type 2 diabetes trial

A continuous glucose monitoring (CGM) device has shown to be safe and highly accurate in people with type 1 diabetes and type 2 diabetes.
The Eversense CGM system demonstrated more than 93% accuracy of glucose readings from 90 participants with diabetes in a new trial.
The system includes an implantable sensor which lasts for 90 days and measures glucose levels from interstitial fluid below the skin surface.
The Eversense CGM was assessed as part of the PRECISE II study, with researchers primarily monitoring how glucose readings compared to reference values within similar ranges.
The CGM’s high accuracy was complemented by its favourable safety profile, measured by how easily and successfully the device could be inserted and removed, and how many procedure-related adverse events occurred.
The results showed that clinicians with limited to no surgical experience could safely insert and remove the CGM following training. Only one serious adverse event was reported due to sensor insertion or removal.
Due to the CGM’s 93% accuracy and overall safety, Satish Garg, MD, editor-in-chief of Diabetes Technology &Therapeutics, the journal in which the results appear, believes there should be increased optimism regarding the future of CGMs.
“Continuous glucose monitoring is becoming standard of care especially for insulin-requiring patients with diabetes,” said Dr Garg. “Eversense, if approved by the FDA, will become the first implantable CGM system for use lasting at least three months.”
First author Mark Christianse, MD, Leslie Klaff, MD, and colleagues added: “The results from this study demonstrate that the use of a long-term, 90-day, implantable continuous glucose sensor is accurate and safe with high rates of adherence to use.
“Additional clinical studies will be required to evaluate the accuracy and usability of the Eversense CGM system among pediatrics, with reduced calibration frequency, and for extended durations through 180 days.”